HSO’s Part 10 – Why I Do Not Recommend AOR Probiotic 3, a Review

HSO’s Part 10 – Why I Do Not Recommend AOR Probiotic 3, a Review

When I started researching the Advanced Orthomolecular Research Probiotic 3 supplement for this blog post, I believed that one of the bacteria in it, Clostridium butyricum was extremely beneficial. No probiotic supplement is best for everyone. However, when you formulate potentially pathogenic strains that are difficult to reduce if they become pathogenic in a “probiotic” supplement, something must be said. Like most HSO probiotic supplements on the market (except the new version of Prescript Assist) the following probiotic supplement has helped some people recover their digestive health. Though I do not recommend it, I do not outright say it is dangerous and has no merit. It has, however, worsened the digestive health of some people as well and has the potential of causing hospitalization from dysbiosis or worse.

Advanced Orthomolecular Research – Probiotic 3, the Good, the Bad, and the Ugly

First, I want to start by stating that I admire the company that produces Probiotic 3, Advanced Orthomolecular Research. I frequently recommend the use of some of their supplements. Doctor Traj Nibbler started AOR because he was contacted by advocacy groups for people with AIDS to help locate hard to find supplemental formulations to improve their health. Dr. Nibbler discovered that it was difficult to source dietary supplements especially of high quality in large quantities. He decided to start sourcing and compounding his own brand of supplements for the people in the advocacy groups. Dr. Nibbler then begun to standardize some of his formulas and eventually founded the company Advanced Orthomolecular Research to sell quality supplements around the world. AOR brought many essential supplement advancements to the market including D-Ribose, Benfotiamine, sustained release R-lipoic acid, and oxaloacetate (benaGene). I have recommended these supplements in the past to many of my clients, and I am glad that AOR made them widely available to the public.1

Clostridum Butyricum, a “Promising” Probiotic with Sickening Potential

I believed in the past that Clostridium butyricum might be an important “probiotic” for supplementation. One of the bacterial strains that are not included in most probiotic supplements, but I thought should be. The bacteria at first glance appears to be important for proper digestive health. It produces the short chain fatty acid butyrate. Butyrate is a significant energy source for colonic cells, anti-cancerous, increases mitochondrial activity, helps maintain proper integrity of the gut mucosal barrier, reduces inflammation, and improves microbiome health by reducing the chance of developing dysbiosis. C. butyricum is a strictly anaerobic endospore-forming Gram-positive bacteria that is a soil inhabitant in various parts of the world. C. butyricum is also found in our gut microbiome, up to 10-20% of the samples. Though C. Butyricum has been used as a probiotic in Asian countries, it is also known to cause opportunistic infections including dysbiosis, chronic diarrhea, sepsis, foodborne illness, and rarely botulism and necrotizing enterocolitis.2 3 4 5 6

In 1986, the first infant botulism case caused by a BoNT/E-producing C. butyricum strain was reported in Italy. Since then, C. butyricum has been associated with botulism in other countries (i.e. China, India, Japan, Ireland, and the USA).7

NEC is a devastating gastrointestinal disease-causing high morbidity and mortality, affecting predominantly preterm neonates during outbreaks. Its clinical presentation is characterized by abdominal distension, gastrointestinal bleeding, mucosal ulcerations and necrosis, portal venous gas, and pneumatosis intestinalis, with different degrees of severity. Despite decades of research, the pathogenesis of NEC remains elusive. Although no aetiological microorganism has been definitively established, the most often implicated bacteria have been Clostridium species. Howard et al. first described an association between C. butyricum and NEC in 1977. They identified C. butyricum in blood and stool cultures in nine of ten preterm neonates during an outbreak of NEC. In another study, Gorham et al. reported the presence of C. butyricum on the hands of members of the medical and nursing staff during an NEC outbreak. This was consistent with the effectiveness of preventive measures in controlling such outbreaks. Additionally, Sturm et al. demonstrated a cytotoxic effect of the supernatant of a C. butyricum strain isolated from a preterm neonate with NEC. Recently, Smith et al.detected the presence of C. butyricum with high density in two surgical samples from preterm neonates with NEC. Both specimens were characterized by histological pneumatosis intestinalis. In a previous study, we analysed 30 stool samples from preterm neonates with and without NEC by using 16S rRNA pyrosequencing and culture-based methods, and 163 samples by using C. butyricum qPCR ; C. butyricum was specifically associated with NEC, and culture supernatants of C. butyricum strains from preterm neonates with NEC showed significant cytotoxic activity8

A new pathogenic C. butyricum strain (NOR33234) has recently been isolated from an elderly patient with antibiotic-associated diarrhoea; tests for C. difficile toxins gave negative results.9

To the best of our knowledge, only one case has been reported of C. butyricum bacteraemia and sepsis, which occurred in an injecting drug user.10 11

There are many different individual strains of the bacteria, some containing more virulence factors than other strains. The strain used in Probiotic 3 is Clostridium butyricum TO-A. C. butyricum TO-A has been shown in one study to potentially reduce inflammation in the colon by deactivating toll-like receptor 4 (TLR4) by the production and utilization of butyrate. TLR4 is a protein when activated leads to a release of nuclear factor kappa-light-chain-enhancer of activated B cells and inflammatory cytokines that activate the innate immune system and sometimes trigger beneficial inflammation. Lipopolysaccharide (LPS) a component of the cell wall of Gram-negative bacteria activates the production of TLR4. An overactivation of TLR4 can trigger excessive inflammation in the digestive tract leading to leaky gut (by weakening the gut junctions), inflammatory bowel disease, and even colorectal cancer if prolonged and severe enough. C. butyricum TO-A supplementation sounds like a good idea if you are dealing with leaky gut, colorectal cancer, or uncontrolled intestinal inflammation, but I do have some issues with suggesting the use of the probiotic in people suffering from these conditions.12

The most common C. butyricum “probiotic” used for supplements is Clostridium butyricum MIYAIRI 588. C. butyricum MIYAIRI 588 has been tested and does not appear to contain any toxin genes and showed antibiotic sensitivity. “Safety studies of this probiotic strain have been conducted and include assessment of antimicrobial sensitivity, documentation of the lack of Clostridium toxin genes, and evaluation of CBM 588®on reproductive and developmental toxicity in a rodent model. With the exception of aminoglycosides, to which anaerobes are intrinsically resistant, CBM 588® showed sensitivity to all antibiotic classes important in human and animal therapeutics. In addition, analysis of the CBM 588® genome established the absence of genes for encoding for α, β, or ε toxins and botulin neurotoxins types A, B, E, or F. There were no deleterious reproductive and developmental effects observed in mice associated with the administration of CBM 588®. “ The only study we have on its virulence ability however was founded by the pharmaceutical company that produces the probiotic strain, Miyarisan Pharmaceutical Co. LTD, Tokyo, Japan. So before I recommend this strain more studies should be performed without the financial sponsorship of the production company before I can recommend the strain. The Clostridium strain that is in Probiotic 3, C. butyricum TO-A, has no virulence testing performed that is published to my knowledge, so it is unknown if the strain is pathogenic or contains the ability to inherit pathogency.13 14

It might be possible for C. butyricum TO-A to obtain virulence potential from other bacteria through horizontal gene transfer. Horizontal gene transfer is the movement of genetic material between unicellular organisms, which can occur from bacteria to bacteria contact, transduction (bacterial DNA being transferred by a virus), or through transformation (when bacteria take components of dead bacteria or organism DNA into their genetic makeup). C. butyricum can inherit the ability to cause botulism. “Notably, the operon encoding the BoNT/E toxin harboured by the neurotoxigenic C. butyricum strains is very similar to that carried by group II type E toxin-producing C. botulinum strains. The presence of the BoNT/E toxin gene within either plasmids or the chromosome in different Clostridium species is consistent with horizontal transfer events mediated by plasmids or phage, and recombination events mediated by mobile genetic elements such as transposons.” Finally, it is possible for C. butyricum to acquire virulence factors from C. difficile leading to chronic diarrhea.“Among the proteins annotated from genome sequencing of this strain, there was an enterotoxin (OA81_00270). Moreover, two annotated proteins had sequence similarity to phage holins in C. botulinum. A previous report has shown that holin-like tcdE is required for exporting enterotoxins tcdA and tcdB in C. difficile. Whether the enterotoxin or holin plays a pathogenic role in C. butyricum infection remains to be examined.”15 16

Enterococcus Faecium, Avoid Supplementation at All Cost

Enterococcus faecium is a Gram-positive bacterium that is a commonly found opportunistic bacteria in our digestive tract. E. faecium is known to cause sepsis, endocarditis, and urinary tract infections. Most strains of E. faecium also have multi-drug antibiotic resistance and show resistance to hand washing and alcohol sanitization. Forty percent of medical intensive care units reportedly found that 80% to 90.4%, of device-associated infections (central lines, prosthetic heart valves, ventilators, and urinary catheters) were due to vancomycin and ampicillin resistant strains of E.faecium. Enterococci bacteria account for at least 12% of nosocomial (hospital) infections in the United States. Vancomycin and ampicillin resistant strains of E. faecium might be susceptible to the antibiotics linezolid, quinupristin-dalfopristin, and daptomycin. The strain of E. faecium used in Probiotic 3 is Enterococcus faecium TO-A.17 18 19 20

It is unknown if Enterococcus faecium TO-A contains any virulence factors associated with E. faecium. We do know that one of the common probiotic strains of E. faecium, E. faecium T-110 has virulence factors can produce biofilm, evade the immune system (anti-phagocytosis), produce hyaluronidase enzyme that breaks down tissue to increase virulence), and adhere to specific bodily tissues (gastrointestinal tract and the heart). Even the supposed “non-pathogenic” strain E. faecium NRRL can produce biofilm, evade the immune system (anti-phagocytosis), and adhere to specific bodily tissues (gastrointestinal tract and the heart). In studies antibiotic resistance has been inherited from horizontal gene transfer and maybe possibly virulence factors from other Enterococci including E. faecalis.21

You might be asking yourself, why include such an “opportunistic” bacterium in a probiotic “supplement”? I thought about it for a while. The only reason I can think of is to reduce the colonies of other “weaker” opportunistic strains that are causing digestive issues in the hope you improve. The risk of relieving bacterial dysbiosis and potentially causing another dysbiosis that could be worse using this bacterium is too great of a risk if you ask me.

Finally, Probiotic 3 Contains the HSO “Probiotic” Bacillus Subtilis

I have written about Bacillus subtilis previously. Probiotic 3 uses the strain Bacillus subtilis TO-A and it’s virulence potential is unknown currently, therefore I do not recommend it.

Final Thoughts

Though I like Advanced Orthomolecular Research and recommend many of their supplements I cannot recommend their main probiotic supplement, Probiotic 3. The opportunistic potential of the three bacteria that are used in the probiotic, C. butyricum, E. faecium, and B. subtilis is too high. If you have taken Probiotic 3 and it is helped or harmed your health please let me know in the comment section of the blog.

  1. https://aor.us/about-us
  2. https://www.sciencedirect.com/science/article/pii/S1198743X15009143
  3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070119/
  4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4903954/
  5. https://www.selfhacked.com/blog/butyrate-health-benefits-butyrate-derivatives-sodium-butyrate-phenylbutyrate-trybutyrine-butyric-acid-butyrate-prodrugs-butyrate-producing-bacteria/
  6. https://www.nature.com/articles/s41398-017-0089-z
  7. https://www.sciencedirect.com/science/article/pii/S1198743X15009143
  8. https://www.sciencedirect.com/science/article/pii/S1198743X15009143
  9. https://www.sciencedirect.com/science/article/pii/S1198743X15009143
  10. https://www.sciencedirect.com/science/article/pii/S1198743X15009143
  11. http://jmm.microbiologyresearch.org/deliver/fulltext/jmm/57/2/236.pdf?itemId=/content/journal/jmm/10.1099/jmm.0.47578-0mimeType=application/pdf
  12. https://www.ncbi.nlm.nih.gov/pubmed/17404865
  13. https://www.ncbi.nlm.nih.gov/pubmed/26437792
  14. http://www.miyarisan.com/english_index.htm
  15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187160/
  16. https://www.sciencedirect.com/science/article/pii/S1198743X15009143
  17. https://academic.oup.com/cid/article/32/9/1384/292320
  18. https://www.semanticscholar.org/paper/First-complete-genome-sequence-of-a-probiotic-T-110-Natarajan-Parani/93be6725d9aa6cb11eab10af238b4f0793bbb6a1
  19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492516/
  20. https://www.ncbi.nlm.nih.gov/books/NBK190429/
  21. https://www.semanticscholar.org/paper/First-complete-genome-sequence-of-a-probiotic-T-110-Natarajan-Parani/93be6725d9aa6cb11eab10af238b4f0793bbb6a1

Leave a Reply